AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial [0.03%]
基于人工智能的病理学分类器可预测恩杂鲁胺治疗转移性激素敏感前列腺癌敏感性的生物标志物分析:来自ENZAMET试验的资料
Sebastian Medina,Naoto Tokuyama,Vaishnavi Putcha et al.
Sebastian Medina et al.
Purpose: The ENZAMET trial established that enzalutamide added to androgen deprivation therapy (ADT) improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), but treatment response is hetero...
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer [0.03%]
纳武单抗联合伊匹单抗一线治疗晚期非小细胞肺癌的早期疗效和安全性分析
Hossein Borghaei,David Balli,Luis G Paz-Ares et al.
Hossein Borghaei et al.
Purpose: To identify variables associated with early detriment on first-line dual immunotherapy from the phase III CheckMate 227 and CheckMate 9LA studies. ...
Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma [0.03%]
帕博利珠单抗联合同期放化疗治疗高危头颈部鳞癌患者的肿瘤和系统性免疫标志与疗效相关性研究
Lazar Vujanovic,Pedro Torres-Saavedra,Fei Tu et al.
Lazar Vujanovic et al.
Purpose: Patients with pathologically high-risk, HPV-negative HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). As CRT can upregulate PD-1/L1 immune checkpoints, adding pembrolizumab may reverse t...
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer [0.03%]
帕博利珠单抗联合二甲双胍治疗转移性头颈部癌症患者的II期可行性研究
Olga Zamulko,Sam Nusbaum,Andrew Osterburg et al.
Olga Zamulko et al.
Background: Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study [0.03%]
一项针对转移性PDAC患者的II期、开放标签、随机对照研究,评估TGFβ抗体NIS793联合白蛋白结合型紫杉醇/吉西他滨对比安慰剂联合白蛋白结合型紫杉醇/吉西他滨的生物标志物分析
Marc Pelletier,Jie Yang,Mukta Joshi et al.
Marc Pelletier et al.
Background: Transforming Growth Factor Beta (TGFβ) plays a dual role in cancer, acting as a tumor suppressor early in disease but promoting progression and immune evasion when dysregulated. In pancreatic ductal adenocarc...
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors [0.03%]
MYC、MYCL和MYCN扩增的实体肿瘤的基因组景观
Matteo Repetto,Allison L Richards,Monica F Chen et al.
Matteo Repetto et al.
Purpose: MYC, MYCN and MYCL amplifications are recurrent oncogenic events across solid tumors. Currently, no standardized selection biomarker is available to identify patients with MYC-dependent tumors. ...
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia [0.03%]
复发/难治性急性髓系白血病患者中临床试验药物与二线挽救治疗的比较研究
Daniel Nguyen,Hagop M Kantarjian,Aram Bidikian et al.
Daniel Nguyen et al.
Purpose: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conve...
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma [0.03%]
针对难治或复发性神经母细胞瘤患者比较第二代和第三代L1CAM特异性CAR-T细胞的首个人体I期ENCIT01试验
Navin Pinto,Annette Künkele,Catherine M Albert et al.
Navin Pinto et al.
Purpose: Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 (NCT02311621) was a first-in-human clinical trial for patients with relapsed and refractory neuroblastoma using chimeric antig...
A multicentre phase 2 study of trifluridine/tipiracil in recurrent/metastatic platinum resistant nasopharyngeal carcinomas [0.03%]
特氟瑞/ tipiracil治疗复发/转移性铂类耐药鼻咽癌的多中心二期临床研究
Jia Li Low,Wan Qin Chong,Edwin Pun Hui et al.
Jia Li Low et al.
Purpose: Therapeutic options beyond platinum, gemcitabine and immunotherapy in r/m NPC remain limited. Median overall survival for R/M disease is 20 months. This study evaluated the efficacy and safety of FTD/TPI in plati...
Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer [0.03%]
脉冲电场消融可重新编程非小细胞肺癌患者的肿瘤免疫并刺激 tertiary lymphoid structure 中生发中心的形成
Marcelo Jimenez,Beryl A Hatton,Alicia Moreno-Gonzalez et al.
Marcelo Jimenez et al.
Purpose: This treat-and-resect clinical study evaluated a specialized form of pulsed electric field (PEF) ablation's potential to modulate antitumor immunity in early-stage non-small cell lung cancer (NSCLC). Tertiary lym...